PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. GL Pharma UK Ltd
GP

GL Pharma UK Ltd

Ely
SME

GL Pharma UK Ltd develops, produces, and allocates unique brand name products as well as generics for the treatment of severe and chronic conditions. They are committed to pharmaceutical research and development.

gl-pharma.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£407.9m
Live
7
Buyers
4
12m
£407.9m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts7 / 10
  • Top buyers4
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — GL Pharma UK LtdUpdated 13 Jul 2026

At a glance · for buyers and watchdogs

GL Pharma UK Ltd has won £407.9m across 4 public-sector buyers, with 7 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
7 of 10Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 3
Drug SafetyResearch & DevelopmentFocused on innovative and generic proprietary developments. ↗Substitution TherapyAddresses drug addiction and related diseases. ↗

Extracted automatically from gl-pharma.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 7 live · 3 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Generics Pharmaceuticals - Supply Chain Resilience
NHS England—01 Sept 2026£4.2m1.8 yrspending
NHS National Generic Pharmaceuticals - Wave 15c
NHS England—01 Jun 2026£403.7m2 yrspending
Potassium iodide tablets
UK HEALTH AND SECURITY AGENCY3360000001 May 2024£11.8 yrsClosed
NHS National Generic Pharmaceuticals - Wave 15c
NHS England————Live
NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 1 May 2025
NHS England33600000———Live
Potassium iodide tablets 2024-2026
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency————Live
NHS National Generic Pharmaceuticals Wave 15a
NHS England33600000———Live
Generic, Branded Generic & Proprietary Medicinal Products - Group 13
Procurement and Logistics Service————Live
NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals
NHS England33600000———Live
NHS National Generic Pharmaceuticals Wave 15b
NHS England33600000———Live
Total live value — · mean award £40.8m

Top buyers · 4 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
7 contracts
100%
since 2026
2
UK HEALTH AND SECURITY AGENCY
1 contract
0%
since 2024
3
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
1 contract
0%
4
Procurement and Logistics Service
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire7 contracts
100%
London1 contract
0%
Northern Ireland1 contract
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). GL Pharma UK Ltd highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
GP
GL Pharma UK Ltd
Yes£407.9m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2025
Confirmation statement
Up to date
Next due 14 Mar 2027
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
11829209
Status
Active
Type
Private limited
Incorporated
15 Feb 2019
Reg. office
Suite 3a, 30 St Thomas Place, Ely, CB7 4EX
SIC codes
46460 · 96090
Last accounts
31 Dec 2025
Next accounts due
30 Sept 2027

Directors & PSC

  • BARTENSTEIN, Michael — director
    Appointed 02 Oct 2023
  • HOMENT, Matthew Peter — director
    Appointed 02 Oct 2023
  • Dr Martin Bartenstein — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
G.L. PHARMA UK LIMITED
11829209 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.